Latest Period
Q4 2025
Security Snapshot
Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share (CABA) Institutional Ownership
CUSIP: 12674W109
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
93
Shares (Excl. Options)
76,246,689
Price
$2.19
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- CABA on Nasdaq
- Shares outstanding
- 96,806,849
- Price per share
- $3.01
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 76,246,689
- Total reported value
- $166,934,120
- % of total 13F portfolios
- 0%
- Share change
- +6,565,338
- Value change
- +$13,771,729
- Number of holders
- 93
- Price from insider filings
- $3.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CABA - Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 12674W109.
- 93 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 93 to 12 between Q4 2025 and Q1 2026.
- Reported value moved from $166,934,120 to $1,502,696.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 93 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 12674W109?
CUSIP 12674W109 identifies CABA - Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 12674W109:
Significant Owners of Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share (CABA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PRUDENTIAL FINANCIAL INC | 8.9% | +21% | $29,447,817 | +$5,132,486 | 12,584,537 | +21% | PRUDENTIAL FINANCIAL INC | 30 Sep 2025 |
| JENNISON ASSOCIATES LLC | 8.9% | +24% | $29,447,817 | +$5,797,046 | 12,584,537 | +25% | Jennison Associates LLC | 30 Sep 2025 |
| T. Rowe Price Investment Management, Inc. | 10% | -10% | $21,589,583 | -$1,099,531 | 9,858,257 | -4.8% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
| Bain Capital Life Sciences Opportunities III, LP | 10% | $15,483,400 | 9,677,125 | Bain Capital Life Sciences Opportunities III, LP | 30 Jun 2025 | |||
| Cormorant Asset Management, LP | 9.3% | -7.1% | $20,586,000 | -$420,443 | 9,400,000 | -2% | Cormorant Asset Management, LP | 31 Dec 2025 |
| Adage Capital Management, L.P. | 10% | $14,404,128 | 9,002,580 | Adage Capital Management, L.P. | 30 Jun 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 5.3% | $15,494,904 | 5,130,763 | Millennium Management LLC | 11 Feb 2026 | |||
| Alyeska Investment Group, L.P. | 4.7% | -23% | $9,855,000 | -$2,847,000 | 4,500,000 | -22% | Alyeska Investment Group, L.P. | 31 Dec 2025 |
| VANGUARD GROUP INC | 3.8% | $5,245,105 | 3,450,727 | The Vanguard Group | 30 Jun 2025 | |||
| CITADEL ADVISORS LLC | 3.4% | -36% | $7,371,644 | -$3,903,787 | 3,150,275 | -35% | Kenneth Griffin | 30 Sep 2025 |
| Nichtberger Steven | 3.3% | $4,855,198 | 3,034,499 | Nichtberger Steven | 30 Jun 2025 | |||
| BlackRock, Inc. | 1% | -86% | $1,359,774 | -$3,803,722 | 894,647 | -74% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 93 institutional investors reported holding 76,246,689 shares of Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share (CABA). This represents 79% of the company’s total 96,806,849 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share (CABA) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10% | 9,858,257 | +18% | 0.01% | $21,590,000 |
| Bain Capital Life Sciences Investors, LLC | 10% | 9,677,125 | 0% | 1.6% | $21,192,904 |
| JENNISON ASSOCIATES LLC | 9.2% | 8,905,699 | +4.8% | 0.01% | $19,503,481 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.1% | 8,829,758 | 0% | 0.03% | $19,337,170 |
| VANGUARD GROUP INC | 4.6% | 4,419,458 | +5.5% | 0% | $9,678,613 |
| Cormorant Asset Management, LP | 4.5% | 4,400,000 | -12% | 0.55% | $9,636,000 |
| MILLENNIUM MANAGEMENT LLC | 2.8% | 2,736,912 | +298% | 0% | $5,993,837 |
| BlackRock, Inc. | 2.4% | 2,328,470 | +44% | 0% | $5,099,349 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 2.3% | 2,253,550 | +46% | 2.6% | $4,935,275 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 1,839,799 | +291% | 0.01% | $4,029,160 |
| RENAISSANCE TECHNOLOGIES LLC | 1.6% | 1,522,583 | +14% | 0.01% | $3,334,457 |
| MORGAN STANLEY | 1.4% | 1,343,708 | -8.9% | 0% | $2,942,720 |
| Woodline Partners LP | 1.3% | 1,250,242 | -41% | 0.01% | $2,738,030 |
| Schonfeld Strategic Advisors LLC | 1.2% | 1,204,070 | +15% | 0.01% | $2,636,910 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | 1,093,959 | -16% | 0% | $2,397,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 1,085,816 | +18% | 0% | $2,378,961 |
| MARSHALL WACE, LLP | 0.99% | 959,076 | -28% | 0% | $2,100,376 |
| Opaleye Management Inc. | 0.93% | 900,000 | +11% | 0.26% | $1,971,000 |
| Ikarian Capital, LLC | 0.93% | 900,000 | 0.26% | $1,971,000 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.78% | 756,637 | 0% | $1,626,770 | |
| TWO SIGMA ADVISERS, LP | 0.76% | 737,900 | +123% | 0% | $1,616,001 |
| BURKEHILL GLOBAL MANAGEMENT, LP | 0.72% | 700,000 | 0% | 0.1% | $1,533,000 |
| JANE STREET GROUP, LLC | 0.68% | 662,149 | +533% | 0% | $1,450,107 |
| Ensign Peak Advisors, Inc | 0.57% | 550,000 | 0% | $1,204,500 | |
| KVP Capital Advisors, LP | 0.52% | 505,431 | 0% | 1.1% | $1,106,894 |
Institutional Holders of Cabaletta Bio, Inc. - Common Stock, par value $0.00001 per share (CABA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 595,426 | $1,502,696 | +$9,008 | $2.69 | 12 |
| 2025 Q4 | 76,246,689 | $166,934,120 | +$13,771,729 | $2.19 | 93 |
| 2025 Q3 | 71,298,009 | $166,850,266 | -$6,956,298 | $2.34 | 75 |
| 2025 Q2 | 72,777,604 | $110,698,611 | +$55,724,802 | $1.52 | 85 |
| 2025 Q1 | 36,304,416 | $50,331,609 | -$5,413,459 | $1.38 | 91 |
| 2024 Q4 | 38,433,072 | $87,226,012 | -$42,983,423 | $2.27 | 104 |
| 2024 Q3 | 48,049,164 | $226,748,702 | -$34,699,190 | $4.72 | 116 |
| 2024 Q2 | 50,801,335 | $379,995,301 | -$32,124,100 | $7.48 | 137 |
| 2024 Q1 | 51,050,542 | $870,921,299 | +$27,212,602 | $17.06 | 157 |
| 2023 Q4 | 48,539,586 | $1,101,850,659 | +$176,650,504 | $22.70 | 128 |
| 2023 Q3 | 40,903,546 | $622,571,929 | +$72,079,488 | $15.22 | 97 |
| 2023 Q2 | 36,440,182 | $470,450,874 | +$156,067,581 | $12.91 | 84 |
| 2023 Q1 | 24,651,946 | $203,869,260 | +$38,611,553 | $8.27 | 70 |
| 2022 Q4 | 19,878,011 | $183,868,921 | +$77,826,088 | $9.25 | 60 |
| 2022 Q3 | 11,928,226 | $7,751,081 | -$5,492,347 | $0.65 | 45 |
| 2022 Q2 | 16,803,742 | $17,812,960 | -$3,030,205 | $1.06 | 48 |
| 2022 Q1 | 18,183,343 | $36,877,990 | -$1,968,981 | $2.03 | 56 |
| 2021 Q4 | 18,168,410 | $68,859,189 | -$10,075,938 | $3.79 | 60 |
| 2021 Q3 | 17,375,298 | $211,265,514 | +$20,553,121 | $12.16 | 60 |
| 2021 Q2 | 15,752,840 | $135,465,315 | -$5,391,551 | $8.60 | 60 |
| 2021 Q1 | 16,228,404 | $180,131,214 | +$595,907 | $11.10 | 67 |
| 2020 Q4 | 16,173,259 | $201,828,469 | -$2,182,506 | $12.48 | 54 |
| 2020 Q3 | 16,353,879 | $177,273,014 | -$991,132 | $10.84 | 54 |
| 2020 Q2 | 16,442,959 | $183,160,097 | +$5,139,597 | $11.14 | 51 |
| 2020 Q1 | 16,009,620 | $116,871,000 | -$3,057,830 | $7.30 | 41 |
| 2019 Q4 | 16,265,458 | $227,227,000 | +$175,618,001 | $13.97 | 40 |